

## Product datasheet for RC212413L3V

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## IRS2 (NM\_003749) Human Tagged ORF Clone Lentiviral Particle

**Product data:** 

Product Type: Lentiviral Particles

Product Name: IRS2 (NM 003749) Human Tagged ORF Clone Lentiviral Particle

Symbol: IRS2
Synonyms: IRS-2

Mammalian Cell Puromycin

Selection:

**Vector:** pLenti-C-Myc-DDK-P2A-Puro (PS100092)

 Tag:
 Myc-DDK

 ACCN:
 NM\_003749

 ORF Size:
 4014 bp

ORF Nucleotide

Sequence:

Cytogenetics:

The ORF insert of this clone is exactly the same as(RC212413).

OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through

naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

**OTI Annotation:** This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

**RefSeg:** NM 003749.2

 RefSeq Size:
 7014 bp

 RefSeq ORF:
 4017 bp

 Locus ID:
 8660

 UniProt ID:
 Q9Y4H2

**Protein Families:** Druggable Genome

13q34





## IRS2 (NM\_003749) Human Tagged ORF Clone Lentiviral Particle - RC212413L3V

**Protein Pathways:** Adipocytokine signaling pathway, Insulin signaling pathway, Neurotrophin signaling pathway,

Type II diabetes mellitus

MW: 137.3 kDa

**Gene Summary:** This gene encodes the insulin receptor substrate 2, a cytoplasmic signaling molecule that

mediates effects of insulin, insulin-like growth factor 1, and other cytokines by acting as a molecular adaptor between diverse receptor tyrosine kinases and downstream effectors. The product of this gene is phosphorylated by the insulin receptor tyrosine kinase upon receptor stimulation, as well as by an interleukin 4 receptor-associated kinase in response to IL4

treatment. [provided by RefSeq, Jul 2008]